FDA authorizes first next generation sequencing-based test to detect very low levels of remaining cancer cells in patients with acute lymphoblastic leukemia or multiple myeloma
(Source: Food and Drug Administration)
Source: Food and Drug Administration - September 28, 2018 Category: American Health Source Type: news
BLINCYTO ® (blinatumomab) Approved In Japan For The Treatment Of Relapsed Or Refractory B-cell Acute Lymphoblastic Leukemia
First Approved Oncology Treatment From Amgen Astellas Joint Venture
BLINCYTO is the First-and-Only Approved CD19-Directed CD3 Bispecific T Cell Engager (BiTE®) Immunotherapy
THOUSAND OAKS, Calif., Sept. 24, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Japanese Ministry of Health, Labour and Welfare has granted marketing approval for BLINCYTO® (blinatumomab) for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). BLINCYTO was developed in Japan by Amgen Astellas BioPharma K.K. (AABP), a joint venture between Amgen and Astellas Pharma Inc., a pharmaceutical compan...
Source: Amgen News Release - September 25, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Acute Lymphoblastic Leukemia (ALL)
Second Orphan Drug Designation for OBI-3424, a novel first-in-class targeted therapy for solid and liquid tumors that express aldo-keto reductase 1c3 (AKR1C3) enzyme
TAIPEI, Taiwan, Sept. 19, 2018 -- (Healthcare Sales & Marketing Network) -- OBI Pharma... Biopharmaceuticals, Oncology, FDA OBI Pharma, Acute Lymphoblastic Leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 19, 2018 Category: Pharmaceuticals Source Type: news
Children who develop ALL may have dysregulated immune function at birth
(American Association for Cancer Research) Neonatal concentrations of eight detectable inflammatory markers were significantly different in children later diagnosed with B-cell precursor acute lymphoblastic leukemia (ALL) compared with controls. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 14, 2018 Category: Cancer & Oncology Source Type: news
Double the Risk for Neurotoxicity for Hispanic Kids From ALL Rx Double the Risk for Neurotoxicity for Hispanic Kids From ALL Rx
Minority children, notably Hispanics, are more susceptible to developing methotrexate-induced neurotoxicity than non-Hispanic children during treatment for acute lymphoblastic leukemia (ALL).Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 12, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
St. Jude researchers solve a central mystery of a baffling high-risk leukemia
(St. Jude Children's Research Hospital) St. Jude Children's Research Hospital investigators have unraveled the origins and identified mutations associated with a perplexing form of acute leukemia. The landmark study appears today as an advance online publication in the journal Nature and lays the foundation for more effective treatment of patients with the high-risk cancer.Their treatment is complicated because MPAL does not fit cleanly into a single diagnosis, but includes features of both acute lymphoblastic leukemia and acute myeloid leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 12, 2018 Category: Cancer & Oncology Source Type: news
Johns Hopkins All Children's becomes first Florida pediatric hospital to have unique leukemia therapy
Johns Hopkins All Children ’s Hospital is now the first pediatric hospital in Florida offering a cutting-edge cellular immunotherapy for advanced leukemia in children and young adults.
It will be offering CAR-T Cell Gene Therapy for leukemia.
Chimeric antigen receptor T-cell therapy, or CAR-T, uses a patient’s own cel ls to fight acute lymphoblastic leukemia, which affects more than 3,000 young people in the U.S. each year. This gene therapy is designed for patients who do not respond to standard… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - August 30, 2018 Category: Health Management Authors: Veronica Brezina-Smith Source Type: news
European Commission Approves BLINCYTO ® (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Approval Based on Data From the Phase 1/2 '205 Study
THOUSAND OAKS, Calif., Aug. 29, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved an expanded indication for BLINCYTO® (blinatumomab) as monotherapy for the treatment of pediatric patients aged one year or older with Philadelphia chromosome-negative CD19 positive B-cell precursor acute lymphoblastic leukemia (ALL), which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation. The approval is based on results...
Source: Amgen News Release - August 29, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Novartis wins EU approval for CAR-T therapy
Novartis announced that the European Commission has approved Kymriah for the treatment of pediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukemia. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - August 27, 2018 Category: Pharmaceuticals Source Type: news
Novartis receives European Commission approval of its CAR-T cell therapy, Kymriah ® (tisagenlecleucel)
Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse; and for the treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. (Source: World Pharma News)
Source: World Pharma News - August 27, 2018 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news
Connectome organization in childhood ALL and risk of delayed neurodevelopment
(Mary Ann Liebert, Inc./Genetic Engineering News) A new study provides novel insights into the cognitive effects of childhood acute lymphoblastic leukemia (ALL) and of chemotherapeutic treatment in long-term survivors of ALL. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 27, 2018 Category: Cancer & Oncology Source Type: news
UCLA Health joins nationwide clinical trial for acute myeloid leukemia
UCLA Health has joined an important national clinical trial that uses genetic testing to match people who have acute myeloid leukemia, or AML, with new therapies. UCLA ’s hospital system is the first in California to offer people the opportunity to participate.The Beat AML Master Trial will evaluate a precision-based medicine approach to treating the disease; it will allow people with the disease to have immediate access to new treatments that are currently in development without having to try more traditional approaches first. The approach could streamline a patient ’s course of treatment and, ultimately, save more li...
Source: UCLA Newsroom: Health Sciences - August 8, 2018 Category: Universities & Medical Training Source Type: news
Comprehensive pediatric CAR T guidelines developed by MD Anderson and PALISI
(University of Texas M. D. Anderson Cancer Center) Almost one year after the US Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) T-cell therapy for children with acute lymphoblastic leukemia (ALL), researchers at The University of Texas MD Anderson Cancer Center and the Pediatric Acute Lung Injury and Sepsis Investigators Network (PALISI) today published treatment guidelines for managing the treatment in the online issue of Nature Reviews Clinical Oncology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 6, 2018 Category: Cancer & Oncology Source Type: news
Chemotherapy May Alter Brain Activity in Survivors of Childhood ALL Chemotherapy May Alter Brain Activity in Survivors of Childhood ALL
Chemotherapy for childhood acute lymphoblastic leukemia (ALL) is associated with alterations in brain activation during attention and executive-function tasks, researchers report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 29, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news
Amgen Receives European Commission Approval To Add Overall Survival Data To BLINCYTO ® (blinatumomab) Label
BLINCYTO is the First-and-Only Approved Bispecific CD19-Directed CD3 T Cell Engager (BiTE®) Immunotherapy
THOUSAND OAKS, Calif., June 19, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted a full marketing authorization for BLINCYTO® (blinatumomab) based on the overall survival (OS) data from the Phase 3 TOWER study in adult patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
"BLINCYTO is the first single agent immunotherapy to demonstrate superior overall survival benefit over standard...
Source: Amgen News Release - June 19, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
